Metagenomi Therapeutics (MGX) Cash & Equivalents (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Cash & Equivalents data on file, last reported at $25.3 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $25.3 million, down 13.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (down 13.32% YoY), and the FY2025 annual result was $41.7 million, up 52.35% from the prior year.
• Cash & Equivalents eased to $25.3 million in Q1 2026 per MGX's latest filing, from $41.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $140.6 million in Q4 2023 and troughed at $25.1 million in Q3 2024.
• A 4-year average of $58.6 million and a median of $41.7 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 80.52% in 2024, then jumped 52.35% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $140.6 million in 2023, then tumbled by 80.52% to $27.4 million in 2024, then jumped by 52.35% to $41.7 million in 2025, then slumped by 39.35% to $25.3 million in 2026.
• Business Quant data shows MGX's Cash & Equivalents at $25.3 million in Q1 2026, $41.7 million in Q4 2025, and $32.8 million in Q3 2025.